Loading…
← CockpitCompetitor Analysis › 600211.SS Tibet Rhodiola Pharmaceutical Holding Co. Class AOpen in the cockpit ↗

Tibet Rhodiola Pharmaceutical Holding Co. Class A600211.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Tibet-based drugmaker; main product Xinhuosu, an injected recombinant BNP drug for acute heart failure, plus Tibetan and Chinese medicines.

Momentum leader 88
Mkt cap
$1.87B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$22.0M
20-day average traded
Fwd P/E
12.5×
forward earnings
ROIC−WACC
+31.2 pp
WACC 7.5%
Hurdle
-18 pp
Req g minus delivered
Close · CNYCN¥38.70
1D-1.5%
1W-1.8%
1M+6.3%
3M-3.4%
6M-8.4%
YTD-9.1%
1Y-13.7%
ATR %2.5%
52w lowhigh21.0% off high

What Tibet Rhodiola Pharmaceutical does

Tibet-based drugmaker; main product Xinhuosu, an injected recombinant BNP drug for acute heart failure, plus Tibetan and Chinese medicines.

Relies on one drug: Xinhuosu, an injection for acute heart failure that has been the only product of its type made in China, so most sales come from a single product under hospital purchasing rules. Its older Tibetan-herb lines, such as the rhodiola capsules, are far smaller. Capacity is being expanded to meet demand.

Products and services

  • Xinhuosu (recombinant human BNP injection)
  • Nuodikang rhodiola capsules and oral liquid
  • Yimeiduo (isosorbide mononitrate tablets)
  • Other Tibetan and Chinese medicines

Where it sits in the supply chain

  • Pharmaceuticals
  • Biologic and traditional-medicine drugs
  • Cardiovascular biologics

What could go right

  • Xinhuosu volume growth and capacity expansion
  • Heart-failure treatment demand in an ageing population

What could go wrong

  • Dependence on one product
  • Price cuts under centralised procurement

Moat: narrow (IP / patents, regulatory licence). Xinhuosu has long been the only domestic product of its kind, a national class-1 biologic.

Founded: 1999 · Employees: 671

Tibet Rhodiola Pharmaceutical at a glance

Size Tibet Rhodiola Pharmaceutical (600211.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.87B, the 1233rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥38.70 on 18 Nov 2026.

Performance Over six months the shares fell 8.4%, against -9.3% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 12.8% over the last twelve months (peer median +10.7%); the operating margin is 27.5% (peer median 13.3%).

Valuation It trades at 12.5× forward earnings against a peer median of 19.6× (6th cheapest of 19).

Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -18 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 31.2 points above its cost of capital (7.5% WACC).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026600211.SS 94Peer median 93
Six months, rebased to 100: Tibet Rhodiola Pharmaceutical against the median of its 20 peers (local-currency closes).

Tibet Rhodiola Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.07BCN¥2.95BCN¥2.78BCN¥3.10BCN¥2.53B
Revenue growth—+6%-11%+23%—
Gross profitCN¥2.89BCN¥2.74BCN¥2.58BCN¥2.92BCN¥2.35B
EBITDAn/aCN¥1.00BCN¥968MCN¥1.10BCN¥759M
Net incomeCN¥992MCN¥938MCN¥1.05BCN¥801MCN¥370M
Free cash flowCN¥1.10BCN¥1.01BCN¥979MCN¥1.06BCN¥748M
Capital expenditureCN¥22.1MCN¥16.0MCN¥37.6MCN¥21.7MCN¥102M
Total debtCN¥1.25BCN¥841MCN¥273MCN¥502MCN¥488M

Quarterly statements and history in the cockpit →

Tibet Rhodiola Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%300009PFIZERCOHANCE000908DMPALIVUSSHILPAMED30057360550705124540600201000028ZYMEHRMYRARE301015ONESOURCE002399BHVN600211.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Tibet Rhodiola Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%+100%0×50×100×150×300009PFIZERCOHANCEDMPSHILPAMED3005736055070512600201ZYMEHRMYONESOURCE002399600211.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tibet Rhodiola Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%300009PFIZERDMPALIVUS3005736055070512600201000028HRMY301015002399600211.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Tibet Rhodiola Pharmaceutical is the large dot.

Tibet Rhodiola Pharmaceutical competitors and peer comparison

How Tibet Rhodiola Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tibet Rhodiola Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure600211.SSPeer medianRank in peer set
1-month return+6.3%+0.7%5th highest of 21
6-month return-8.4%-9.3%11th highest of 21
Distance from 52-week high-21.0%-28.3%8th highest of 21
Revenue growth (TTM)+12.8%+10.7%9th highest of 20
Operating margin27.5%13.3%5th highest of 20
Forward P/E12.5×19.6×6th cheapest of 19
Growth the price implies (Req g, 7 yrs)-1.2%3.3%5th least demanding of 13
Growth delivered (Del g)+16.7%+6.8%3rd highest of 13
Hurdle (Req g minus delivered)-18.0 pp-6.3 pp3rd least demanding of 13
ROIC minus cost of capital+31.2 pp+0.1 pp3rd highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%12.5×-1.2%+16.7%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%18.1×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%21.9×11.2%+2.4%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%96.3×n/an/a
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%n/an/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%13.2×-3.4%+8.0%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%23.8×20.1%+6.2%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%54.3×n/an/a
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%13.0×5.4%+29.1%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%15.7×-6.0%+7.4%
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%9.4×1.2%+14.1%
Tsumura & 4540.TJapan$1.93B+6%+13%18%10.4×n/an/a
Jinyu Bio-Technology 600201.SSChina$1.93B-21%+22%10%59.0×23.4%-2.5%
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%10.8×-9.5%+4.2%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%160.4×n/an/a
Harmony Biosciences HRMYUnited States$1.94B+6%+20%22%8.6×-10.5%+40.3%
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%9.6×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%
OneSource Specialty Pharma ONESOURCE.NSIndia$1.95B-14%+11%6%44.6×n/an/a
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%25.8×-0.7%+0.5%
Biohaven BHVNUnited States$1.95B+46%n/an/an/an/an/a

Questions

Which companies are Tibet Rhodiola Pharmaceutical's closest peers?
The cockpit's peer set: Anhui Anke Biotechnology (Group) (300009.SZ), Pfizer (PFIZER.NS), Cohance Lifesciences (COHANCE.NS), CSPC Hunan Jingfeng Pharmaceutical (000908.SZ), Dermapharm (DMP.DE), Alivus Life Sciences (ALIVUS.NS), Shilpa Medicare (SHILPAMED.NS), Shenyang Xingqi Pharmaceutical (300573.SZ).
Is Tibet Rhodiola Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 12.5× against a peer median of 19.6×, 6th cheapest of 19 in its peer set. For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -18 pp: the price already allows for a slowdown.
How has Tibet Rhodiola Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -8.4% against -9.3% for the median peer; over one year -13.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.